novo nordisk glp-1 receptor agonist Trends in the Development of Agonists Novo Nordisk Receives FDA Approval

As a functional medicine physician, Ive witnessed firsthand how these medications are transforming our approach to diabetes, obesity, and cardiometabolic health

It is, however, a foundational strategy that makes any weight management approach, whether pharmaceutical, peptide-based, or lifestyle-only, more effective

Cardiovascular and Metabolic Health Semaglutide has the stronger long-term cardiovascular outcome data , showing reduced risk of major adverse cardiovascular events in high-risk patients with type 2 diabetes

It is letting your GLP-1 receptors upregulate and your stomach motility adjust without triggering the severe nausea that makes patients abandon treatment entirely

Some people may need IV fluids to rehydrate and correct electrolyte imbalances

doi: 10.1016/j.numecd.2021.08.049, 34